<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05080166</url>
  </required_header>
  <id_info>
    <org_study_id>21-409</org_study_id>
    <nct_id>NCT05080166</nct_id>
  </id_info>
  <brief_title>UPLYFT For Lymphoma Survivors</brief_title>
  <official_title>An Intervention for Fear of Cancer Recurrence for Lymphoma Survivors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Society of Hematology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to field test and pilot an intervention called UPLYFT&#xD;
      (Understand and Prevail: Lymphoma Fear of Recurrence Therapy) that includes information about&#xD;
      lymphoma survivorship and tools to improve quality of life and reduce lymphoma-related&#xD;
      worries among lymphoma survivors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a two phase pilot study to develop and pilot the UPLYFT (Understand and Prevail:&#xD;
      Lymphoma Fear of Recurrence Therapy)program intervention that includes lymphoma survivorship&#xD;
      information and acceptance and commitment therapy strategies to alleviate fear of cancer&#xD;
      recurrence, reduce distress, and improve quality of life among lymphoma survivors.&#xD;
&#xD;
      Phase 1 will be a two part development process of the UPLYFT program based on interview&#xD;
      feedback from lymphoma and mental health clinicians and then feedback from a six person group&#xD;
      of lymphoma survivors after participation in an UPLYFT program field test . Phase 2 will then&#xD;
      conduct a full scale pilot study using the UPLFYT program finalized in Phase 1.&#xD;
&#xD;
      Research procedures include:&#xD;
&#xD;
        -  In depth interview (lymphoma and mental health clinicians)&#xD;
&#xD;
        -  Screening for eligibility&#xD;
&#xD;
        -  6 weekly intervention sessions (lymphoma survivors)&#xD;
&#xD;
        -  Baseline Assessments and Questionnaires (lymphoma survivors)&#xD;
&#xD;
           74 people are expected to participate in this study with 14 in Phase 1 and 60 in Phase&#xD;
           2.&#xD;
&#xD;
      American Society of Hematology is providing funding for the trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 30, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility: Enrollment Rate</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Feasibility of the Fear of Cancer Recurrence (FCR) intervention (UPLYFT) defined as ≥50% enrollment of eligible patients approached</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility: Program Session Completion Rate</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Feasibility of the FCR intervention (UPLYFT) defined as ≥ 70% completion of intervention sessions,</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility: Data Collection Completion Rate</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Feasibility of the FCR intervention (UPLYFT) defined as ≥70% completion of patient-reported data collection.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acceptability: Satisfaction Rate</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Acceptability of the FCR intervention (UPLYFT) defined as ≥ 90% satisfaction rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acceptability: Disenrollment Rate</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Acceptability of the FCR intervention (UPLYFT) defined ≤ 10% disenrollment rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary efficacy: Fear of Cancer Recurrence (FCR) Change</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Pre-intervention to post-intervention changes in Fear of Cancer Recurrence (FCR) measured with the Fear of Cancer Recurrence Inventory (42-item questionnaire)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary efficacy: Quality of Life Change</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Pre-intervention to post-intervention changes in quality of life measured with the Quality of Life- Cancer Survivor instrument (a 41-item questionnaire)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary efficacy: Anxiety Change</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Pre-intervention to post-intervention changes in anxiety as measured by the Hospital and Anxiety Scale (Anxiety subscale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary efficacy: Depression Change</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Pre-intervention to post-intervention changes in depression as measured by the Hospital Anxiety and Depression Scale (Depression subscale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary efficacy: Psychological inflexibility Change</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Pre-intervention to post-intervention changes in psychological inflexibility as measured by the Acceptance and Action Questionnaire-II (a 7-item scale)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Lymphoma</condition>
  <condition>Survivorship</condition>
  <arm_group>
    <arm_group_label>Clinicians Interviews</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lymphoma and mental health clinicians will participate in 1x in-depth qualitative interview to provide feedback for the development of the UPLYFT program.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lymphoma Survivors Field Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A six person group of lymphoma survivors will participate in a six session UPLYFT program field test to provide feedback for the development of the UPLYFT program.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UPLYFT Pilot</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lymphoma survivors will participate in the phase 1 finalized, six session UPLYFT program.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Interview with Clinicians</intervention_name>
    <description>One time, qualitative interview of clinicians for feedback on UPLYFT intervention</description>
    <arm_group_label>Clinicians Interviews</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Field Test of UPLYFT with Lymphoma Survivors</intervention_name>
    <description>6 session of UPLYFT intervention with Lymphoma Survivors for feedback</description>
    <arm_group_label>Lymphoma Survivors Field Test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Pilot of UPLYFT with Lymphoma Survivors</intervention_name>
    <description>6 session of UPLYFT intervention with Lymphoma Survivors</description>
    <arm_group_label>UPLYFT Pilot</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Lymphoma Survivors Phase 1 and 2:&#xD;
&#xD;
          -  Diagnosis of lymphoma (indolent non-Hodgkin lymphoma, aggressive non-Hodgkin lymphoma,&#xD;
             or classic Hodgkin lymphoma)&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Interval of 3 months to 24 months from completion of first-line treatment&#xD;
&#xD;
          -  In complete remission after first line of treatment&#xD;
&#xD;
          -  Clinically significant FCR (score of ≥ 16 on the validated FCR Inventory-Severity&#xD;
             Subscale [FCRI-SS).&#xD;
&#xD;
          -  Access to computer (for videoconferencing)&#xD;
&#xD;
        Lymphoma clinicians and mental health clinicians Phase 1:&#xD;
&#xD;
          -  Lymphoma clinicians ≥ 1 year from oncology fellowship completion OR mental health&#xD;
             clinicians (psychologists, social workers, psychiatrists) ≥ 1 year from completion of&#xD;
             clinical training.&#xD;
&#xD;
          -  Longitudinal clinical care for patients with lymphoma by oncologists OR provision of&#xD;
             care for patients with cancer by mental health clinicians&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Lymphoma Survivors Phase 1:&#xD;
&#xD;
          -  Age &lt; 18 years&#xD;
&#xD;
          -  Concurrent other malignancy&#xD;
&#xD;
          -  Patients with uncontrolled/untreated psychotic disorders or untreated bipolar and&#xD;
             borderline personality disorder (as ascertained from medical record screen).&#xD;
&#xD;
        Lymphoma Survivors Phase 2:&#xD;
&#xD;
          -  Age &lt; 18 years&#xD;
&#xD;
          -  Concurrent other malignancy&#xD;
&#xD;
          -  Patients with uncontrolled/untreated psychotic disorders or untreated bipolar and&#xD;
             borderline personality disorders (as ascertained from medical record screen).&#xD;
&#xD;
               -  Our study will exclude members of the following special populations:&#xD;
&#xD;
                    -  Adults unable to consent&#xD;
&#xD;
                    -  Individuals who are not yet adults (infants, children, teenagers)&#xD;
&#xD;
                    -  Pregnant women&#xD;
&#xD;
                    -  Prisoners&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oreofe O Odejide, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oreofe_Odejide@dfci.harvard.edu</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Oreofe O Odejide, MD, MPH</last_name>
    <phone>(617) 632-6864</phone>
    <email>Oreofe_Odejide@dfci.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Oreofe O Odejide, MD, MPH</last_name>
      <phone>617-632-6864</phone>
      <email>Oreofe_Odejide@dfci.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Oreofe O Odejide, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 5, 2021</study_first_submitted>
  <study_first_submitted_qc>October 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2021</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Oreofe O. Odejide</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Lymphoma</keyword>
  <keyword>Survivorship</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Data can be shared no earlier than 1 year following the date of publication</ipd_time_frame>
    <ipd_access_criteria>Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

